- Home
- HUBB vs ROIV Comparison
HUBB vs ROIV Comparison
Compare HUBB & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUBB | ROIV |
|---|---|---|
| Founded | 1888 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5B | 20.7B |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HUBB | ROIV |
|---|---|---|
| Price | $504.62 | $28.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $517.88 | $28.94 |
| AVG Volume (30 Days) | 509.1K | ★ 4.4M |
| Earning Date | 04-30-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 15.10 | N/A |
| EPS | ★ 3.41 | N/A |
| Revenue | ★ $5,844,600,000.00 | $29,053,000.00 |
| Revenue This Year | $10.41 | N/A |
| Revenue Next Year | $5.49 | $744.61 |
| P/E Ratio | $150.63 | ★ N/A |
| Revenue Growth | ★ 3.84 | N/A |
| 52 Week Low | $349.40 | $10.58 |
| 52 Week High | $565.50 | $30.33 |
Technical Indicators
Market Signals| Indicator | HUBB | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 50.50 |
| Support Level | $461.20 | $27.00 |
| Resistance Level | $512.59 | $30.26 |
| Average True Range (ATR) | 15.48 | 0.94 |
| MACD | -6.18 | -0.08 |
| Stochastic Oscillator | 8.85 | 39.10 |
Price Performance
Historical ComparisonAbout HUBB Hubbell Inc
Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, in electrical substations, and in commercial and industrial buildings. The company's primary operations are in the United States, where around 90% of revenue is derived.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.